AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma

Figure 1 Overview of the AKT and ERK signaling pathway.

Figure 2 Light micrograph displaying strong phospho-ERK1/2 (A) and strong phospho-AKT (B) expression as analyzed by immunohistochemistry in intrahepatic cholangiocarcinoma (x 400).

Figure 3 Kaplan-Meier survival plot for disease specific overall survival in the complete series of 62 intrahepatic cholangiocarcinoma in relation to pERK immunostaining intensity. Log-rank test: P = 0.242.

Figure 4 Kaplan-Meier survival plot for disease specific overall survival in the complete series of 59 intrahepatic cholangiocarcinoma in relation to pAKT immunostaining intensity. Log-rank test: P = 0.618.

Figure 5 Intrahepatic cholangiocarcinoma with positive EGFR expression exhibit significantly more frequent AKT activation (χ² analysis: P = 0. 028).